BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29531001)

  • 1. Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients.
    Korkmaz MF; Güzel A; Açıkgöz M; Okuyucu A; Alaçam H
    Ann Clin Lab Sci; 2018 Jan; 48(1):81-89. PubMed ID: 29531001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
    PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study.
    Sardà Sánchez M; Hernández JC; Hernández-Bou S; Teruel GC; Rodríguez JV; Cubells CL
    BMC Res Notes; 2012 Jul; 5():363. PubMed ID: 22818355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
    Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study.
    Alcoba G; Manzano S; Lacroix L; Galetto-Lacour A; Gervaix A
    BMC Infect Dis; 2015 Aug; 15():347. PubMed ID: 26286191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
    Torres A; Ramirez P; Montull B; Menéndez R
    Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children.
    Agnello L; Bellia C; Di Gangi M; Lo Sasso B; Calvaruso L; Bivona G; Scazzone C; Dones P; Ciaccio M
    Clin Biochem; 2016 Jan; 49(1-2):47-50. PubMed ID: 26386341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
    Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
    Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity and Specificity of Soluble Triggering Receptor Expressed on Myeloid Cells-1, Midregional Proatrial Natriuretic Peptide and Midregional Proadrenomedullin for Distinguishing Etiology and to Assess Severity in Community-Acquired Pneumonia.
    Esposito S; Di Gangi M; Cardinale F; Baraldi E; Corsini I; Da Dalt L; Tovo PA; Correra A; Villani A; Sacco O; Tenero L; Dones P; Gambino M; Zampiero A; Principi N;
    PLoS One; 2016; 11(11):e0163262. PubMed ID: 27846213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
    Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
    J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.